quote:Originally posted by Peaser01: Thank my wife.
------------------------------------------------- Well, now that we have your better half back on board we should make some money on her savy..
The lady sure can help you track um down.. Thats cool when you can have an in-house team working well together..
Posts: 10729 | From: oregon | Registered: Feb 2005
| IP: Logged |
Novavax Has 'Significant' Sell-Off Potential Peter Kang, 04.07.06, 3:48 PM ET
RBC Capital Markets downgraded shares of Novavax to "underperform" from "sector perform" and said shares of the tiny drug developer could be set for a decline as concerns of a pandemic avian flu outbreak abate.
"We believe that Novavax's run from under $2 to the current $6 to $7 range over the last six months is based on fear of an avian flu outbreak, not sound fundamental valuation of the company," wrote Ken Trbovich in a recent client note.
The analyst said it believes the company's new vaccine developmental progress is "years behind" competitors such as Chiron (nasdaq: CHIR - news - people ), GlaxoSmithKline (nyse: GSK - news - people ), Sanofi-Aventis and Solvay.
"Novavax likes to position itself as a 'technology leader' in the avian flu market, but closer examination of its competition reveals many companies whose efforts in this area are far more advanced than Novavax's," said the analyst.
Should GlaxoSmithKline and other companies working on a bird flu vaccine hit significant milestones this year, said Trbovich, "Novavax's shares are likely in for a significant correction to the downside."
The research analyst maintained a price target of $3 on the stock: "We believe the valuation is running so far in front of so many other small companies with a focus on flu and other vaccines that the stock has the potential for a significant sell-off when the bird flu scare cools."
Posts: 141 | From: Dallas | Registered: Mar 2006
| IP: Logged |
Novavax Has 'Significant' Sell-Off Potential Peter Kang, 04.07.06, 3:48 PM ET
RBC Capital Markets downgraded shares of Novavax to "underperform" from "sector perform" and said shares of the tiny drug developer could be set for a decline as concerns of a pandemic avian flu outbreak abate.
"We believe that Novavax's run from under $2 to the current $6 to $7 range over the last six months is based on fear of an avian flu outbreak, not sound fundamental valuation of the company," wrote Ken Trbovich in a recent client note.
The analyst said it believes the company's new vaccine developmental progress is "years behind" competitors such as Chiron (nasdaq: CHIR - news - people ), GlaxoSmithKline (nyse: GSK - news - people ), Sanofi-Aventis and Solvay.
"Novavax likes to position itself as a 'technology leader' in the avian flu market, but closer examination of its competition reveals many companies whose efforts in this area are far more advanced than Novavax's," said the analyst.
Should GlaxoSmithKline and other companies working on a bird flu vaccine hit significant milestones this year, said Trbovich, "Novavax's shares are likely in for a significant correction to the downside."
The research analyst maintained a price target of $3 on the stock: "We believe the valuation is running so far in front of so many other small companies with a focus on flu and other vaccines that the stock has the potential for a significant sell-off when the bird flu scare cools."
Posts: 141 | From: Dallas | Registered: Mar 2006
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
